US EditionPublished • loading... • Updated
Novo Nordisk shares tumble as CEO warns it will get worse before it gets better
Novo Nordisk expects 5% to 13% declines in 2026 sales and profit due to U.S. price cuts for Wegovy and rising competition, CEO says price reductions are "painful."
- On Tuesday, Novo Nordisk surprise pre-released its 2026 forecast, prompting investor sell-offs and market panic; the company's main listing fell 18% in Copenhagen early Wednesday, erasing year-to-date gains.
- Pressure from lower U.S. prices and patent expiries forced the downgrade as lower realised U.S. prices, fierce competition and semaglutide patent expiries hit the outlook, with 1.5 million Americans using compounded copycat GLP-1 drugs.
- The company warned that 2026 sales and adjusted operating profit could decline between 5% and 13%, and CEO Mike Doustdar said `People should expect that it goes down before it comes back up`.
- U.S.-Listed depository receipts slid nearly 15% following the guidance surprise, and shares of Eli Lilly, rival drugmaker, also fell as investors fretted about competition.
- Longer term, strong pill demand contrasts with the weaker corporate outlook as oral Wegovy prescriptions hit around 50,000 weekly by January 23 despite ending years-long double-digit gains since Wegovy's launch.
Insights by Ground AI
13 Articles
13 Articles
The actions Novo Nordisk, the producer of Ozempic and Wegovy medicinal products, were completed by 20% on Wednesday, after the Danish pharmaceutical giant warned that it would be faced with price pressures “without prior” in 2026,...
·Romania
Read Full Article
Once they were cashier hitters, now the Danish pharmaceutical company has fallen back in the case of weight loss products. A deal with the Trump administration is also causing pressure.
When Novo Nordisk expects a decline in sales in 2026 in the range of 5 to 13 percent, it is not that the pharmaceutical company expects demand for the company's medicine to fall.
·Aarhus, Denmark
Read Full Article
Novo Nordisk's CEO predicts increased price pressure in the US, but is still optimistic.
·Copenhagen, Denmark
Read Full Article
Coverage Details
Total News Sources13
Leaning Left2Leaning Right1Center6Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 22%
C 67%
11%
Factuality
To view factuality data please Upgrade to Premium
